Immune-mediated necrotizing myositis following SARS-Cov-2: A case report

A 56-year-old woman who had been coughing for 7 weeks was brought to the hospital on April 21, following the sensation of weakness in her lower extremities, then in her upper extremities, and a gradual increase in weakness. Reverse transcriptionpolymerase chain reaction (RT-PCR) testing of coronavirus disease 2019 (COVID-19) was found to be positive. COVID-19 IgG was also positive.Computed tomography (CT) scan of the chest showed patchy ground-glass opacities in the lungs. Muscle enzymes and aldolase were elevated. Muscle MRI showed defined hyperintensity and edema in proximal muscles. Immune mediated necrotizing myositis (IMNM) was recommended in this patient that may have developed following SARS-Cov-2. Treatment was begun with methylprednisolone pulse and intravenous immune globulin (IVIG). Following the start of treatment, the patient's dyspnea and muscle weakness improved. Although IMNM is a rare condition, especially in SARS-Cov-2, it is rapidly debilitating. Physicians need to be more aware of the clinical and paraclinical features and therapeutic approach of IMNM.

Immune-mediated necrotizing myositis following SARS-Cov-2: A case report Keywords:

COVID-19 , Myositis , Necrotizing , SARS-CoV-2